Click on a filter below to refine your search. Remove a filter to broaden your search.
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.